Poor tolerability to ponatinib in Indian CML patients
Blood Adv
.
2020 May 12;4(9):1927-1929.
doi: 10.1182/bloodadvances.2020001944.
Authors
Charanpreet Singh
1
,
Arihant Jain
1
,
Deepesh Lad
1
,
Gaurav Prakash
1
,
Alka Khadwal
1
,
Dinesh Bhurani
2
,
Rayaz Ahmed
2
,
Narendra Agrawal
2
,
Jose Easow
3
,
Neelam Varma
4
,
Pankaj Malhotra
1
Affiliations
1
Clinical Hematology Unit, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
2
Department of Hematology and Bone Marrow Transplant Unit, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India.
3
Department of Medical Oncology, Apollo Hospital, Chennai, India; and.
4
Department of Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
PMID:
32380534
PMCID:
PMC7218412
DOI:
10.1182/bloodadvances.2020001944
No abstract available
Publication types
Comment
MeSH terms
Humans
Imidazoles / adverse effects
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Pyridazines* / adverse effects
Substances
Imidazoles
Pyridazines
ponatinib